Background Pain in PsA has multifaceted origins (e.g., peripheral joint inflammation, axial involvement [axPsA], skin lesions, dactylitis, enthesitis, underlying conditions) and can be difficult to treat. Guselkumab (GUS), a fully human IL-23p19 subunit inhibitor, is effective treating multiple domains elicited durable improvement patient (pt)-reported pain (PtP) the DISCOVER (D)-1&2 trials...

Background. The goal of “treat-to-target” strategy (T2T) in psoriatic arthritis (PsA) is attaining remission or minimal disease activity (MDA). benefits T2T are shown recently the study TICOPA and REMARCA. But prognostic factors for achievement MDA PsA patients (pts) at early-stage hasn’t been studied yet. Objective – to determine associated with within 12 months (mo) treatment according early ...

Psoratic arthritis (PsA) is a common disorder affecting every fifth patient with psoriasis. Typical clinical manifestations of PsA include asymmetric mono/oligoathritis or polyarthritis, spondyloarthritis, enthesitis and dactylitis. More rarely associated uveitis inflammatory bowel disease. Upadacitinib selective JAK-kinase inhibitor approved for treatment PsA. Its efficacy favorable safety pro...

The Cooperative Study of Sickle Cell Disease reported that dactylitis, severe anemia, and leukocytosis in very young children with sickle cell disease (SCD) increased the risk of later adverse outcomes, including death, stroke, frequent pain, and recurrent acute chest syndrome. This model has not been validated in other cohorts. We evaluated its performance in the Dallas Newborn Cohort, a newbo...

Classification Chronic idiopathic arthritis of childhood encompasses a diverse group of disorders. This diversity is reflected in the diVerent classification systems in use in North America and Europe. 2 As concepts have evolved there have been attempts to modify the classification system. This is not just a matter of semantics, but a recognition that it is necessary to develop as much homogene...